JP7538602B2 - ミエリン障害を治療するための組成物および方法 - Google Patents

ミエリン障害を治療するための組成物および方法 Download PDF

Info

Publication number
JP7538602B2
JP7538602B2 JP2019571337A JP2019571337A JP7538602B2 JP 7538602 B2 JP7538602 B2 JP 7538602B2 JP 2019571337 A JP2019571337 A JP 2019571337A JP 2019571337 A JP2019571337 A JP 2019571337A JP 7538602 B2 JP7538602 B2 JP 7538602B2
Authority
JP
Japan
Prior art keywords
isp
disease
lpc
therapeutic
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019571337A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527132A5 (cg-RX-API-DMAC7.html
JP2020527132A (ja
Inventor
シルバー,ジェリー
ルオ,フーチェン
ヤン,ヤン
Original Assignee
ケース ウエスタン リザーブ ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケース ウエスタン リザーブ ユニバーシティ filed Critical ケース ウエスタン リザーブ ユニバーシティ
Publication of JP2020527132A publication Critical patent/JP2020527132A/ja
Publication of JP2020527132A5 publication Critical patent/JP2020527132A5/ja
Application granted granted Critical
Publication of JP7538602B2 publication Critical patent/JP7538602B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1706—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019571337A 2017-07-11 2018-07-11 ミエリン障害を治療するための組成物および方法 Active JP7538602B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762531251P 2017-07-11 2017-07-11
US62/531,251 2017-07-11
PCT/US2018/041636 WO2019014342A1 (en) 2017-07-11 2018-07-11 COMPOSITIONS AND METHODS FOR TREATING MYELIN DISEASES

Publications (3)

Publication Number Publication Date
JP2020527132A JP2020527132A (ja) 2020-09-03
JP2020527132A5 JP2020527132A5 (cg-RX-API-DMAC7.html) 2023-02-13
JP7538602B2 true JP7538602B2 (ja) 2024-08-22

Family

ID=65001812

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019571337A Active JP7538602B2 (ja) 2017-07-11 2018-07-11 ミエリン障害を治療するための組成物および方法

Country Status (9)

Country Link
US (1) US20200230205A1 (cg-RX-API-DMAC7.html)
EP (1) EP3651785B1 (cg-RX-API-DMAC7.html)
JP (1) JP7538602B2 (cg-RX-API-DMAC7.html)
KR (1) KR102772298B1 (cg-RX-API-DMAC7.html)
CN (1) CN111093684A (cg-RX-API-DMAC7.html)
AU (2) AU2018301399B2 (cg-RX-API-DMAC7.html)
CA (1) CA3064463A1 (cg-RX-API-DMAC7.html)
ES (1) ES3056700T3 (cg-RX-API-DMAC7.html)
WO (1) WO2019014342A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022212872A1 (en) * 2021-04-02 2022-10-06 Case Western Reserve University Methods and compositions for accelerating oligodendrocyte maturation
AU2024373065A1 (en) * 2023-11-01 2026-05-21 Biocells (Beijing) Biotech Co., Ltd. Polypeptide derivative, pharmaceutical composition thereof and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015516391A (ja) 2012-04-09 2015-06-11 ケース ウエスタン リザーブ ユニバーシティ Larファミリーホスファターゼの活性を阻害する組成物及び方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4731058A (en) 1986-05-22 1988-03-15 Pharmacia Deltec, Inc. Drug delivery system
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5368562A (en) 1993-07-30 1994-11-29 Pharmacia Deltec, Inc. Systems and methods for operating ambulatory medical devices such as drug delivery devices
GB9718609D0 (en) 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
CA2417454A1 (en) 2000-07-31 2002-02-07 Active Motif Peptide-mediated delivery of molecules into cells
BRPI0616465A2 (pt) * 2005-09-29 2011-06-21 Sanofi Aventis derivados de fenil-[1,2,4]-oxadiazol-5-ona com grupo fenila, bem como seu uso, composição farmacêutica compreendo os mesmos e processo de preparação da referida composição farmacêutica
US10258672B2 (en) * 2014-10-09 2019-04-16 Case Western Reserve University Compositions and methods of treating root avulsion injury

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015516391A (ja) 2012-04-09 2015-06-11 ケース ウエスタン リザーブ ユニバーシティ Larファミリーホスファターゼの活性を阻害する組成物及び方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Inhibitors of myelination: ECM changes, CSPGs and PTPs,Exp Neurol.,Vol. 251,p. 39-46 (page 1-19),doi:10.1016/j.expneurol.2013.10.017.

Also Published As

Publication number Publication date
WO2019014342A1 (en) 2019-01-17
AU2018301399B2 (en) 2024-08-29
EP3651785C0 (en) 2025-11-12
CA3064463A1 (en) 2019-01-17
ES3056700T3 (en) 2026-02-24
AU2024266863A1 (en) 2024-12-12
EP3651785B1 (en) 2025-11-12
KR102772298B1 (ko) 2025-02-25
JP2020527132A (ja) 2020-09-03
CN111093684A (zh) 2020-05-01
EP3651785A1 (en) 2020-05-20
KR20200039621A (ko) 2020-04-16
AU2018301399A1 (en) 2019-12-19
EP3651785A4 (en) 2021-07-07
US20200230205A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
US12129285B2 (en) TDP-43 mitochondrial localization inhibitor for the treatment of neurogenerative disease
AU2024266863A1 (en) Compositions and methods for treating myelin disorders
Ng et al. Liver-specific adiponectin gene therapy suppresses microglial NLRP3-inflammasome activation for treating Alzheimer’s disease
CN107148275A (zh) 包含编码生长因子的外源多核苷酸的稳定的神经干细胞及其使用方法
US10898550B2 (en) Compositions and methods of treating root avulsion injury
EP3967705A1 (en) Rvg derived peptides
US12403184B2 (en) Compositions and methods for treating neurodegenerative disroders
US20200093890A1 (en) Compositions and methods for treating alzheimer's disease
JPWO2007139120A1 (ja) アミロイドβクリアランス促進剤
HK40021220A (en) Compositions and methods for treating myelin disorders
HK40021220B (en) Compositions and methods for treating myelin disorders
US20090111748A1 (en) Fibroblast growth factor-2 promotes neurogenesis and neuroprotection and prolongs survival in huntington's disease
IL154777A (en) Use of il-6 receptor/il-6 chimera for the manufacture of a medicament for treating huntington's disease
AU2001291849A1 (en) Use of IL-6R/IL-6 chimera in Huntington's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221226

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230725

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240221

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240418

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240809

R150 Certificate of patent or registration of utility model

Ref document number: 7538602

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150